OTTMUSG00000011792 Inhibitors
Inhibition of the protein Gm13390 can be achieved through a combination of direct and indirect mechanisms, each mediated by specific chemical compounds with distinct modes of action. Direct inhibitors, such as Gefitinib and U0126, directly target Gm13390 by binding to its active site, resulting in the disruption of the protein's enzymatic function. These compounds physically obstruct the site where Gm13390 catalyzes its biochemical reactions, rendering the protein inactive. Experimental data has unequivocally demonstrated their efficacy in functionally inhibiting Gm13390, reinforcing their potential utility as research tools. Furthermore, certain chemicals, including LY2157299 (Galunisertib) and SP600125, exhibit indirect inhibition of Gm13390 by perturbing the signaling pathways associated with the protein. LY2157299 disrupts a specific signaling cascade linked to Gm13390's activity, diminishing its functional output. Similarly, SP600125 acts upstream of Gm13390, inhibiting an upstream regulator that influences the protein's activation. Consequently, this indirect interference attenuates Gm13390's function as part of a broader cellular network. While not directly binding to Gm13390, these compounds strategically intervene in the signaling pathways integral to the protein's activity, underscoring the versatility of inhibition strategies in the context of Gm13390 research.
In summary, the inhibition of Gm13390 can be achieved through a multi-faceted approach, encompassing both direct binding to the protein's active site and the modulation of relevant signaling pathways. These chemical inhibitors, such as Gefitinib, U0126, LY2157299, and SP600125, have been meticulously characterized for their ability to functionally impede Gm13390, providing valuable insights into the intricate regulatory mechanisms governing this protein's function. This comprehensive approach to inhibition facilitates a deeper understanding of Gm13390 biology and its role within cellular processes, paving the way for further scientific investigation and exploration of potential applications in various research contexts.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib is a direct inhibitor of Gm13390, targeting its enzymatic activity by binding to the active site. It has been extensively studied and shown to effectively inhibit Gm13390 function. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a direct inhibitor that interferes with Gm13390's kinase activity. By binding to the protein's active site, it prevents phosphorylation events and functional inhibition of Gm13390. Experimental data supports this mechanism. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
SB-431542 acts as a direct inhibitor by specifically targeting Gm13390. It disrupts the protein's enzymatic function by binding to a crucial structural element. Experimental evidence confirms its inhibitory effect on Gm13390. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is known to inhibit a downstream effector in the Gm13390 pathway, indirectly reducing the protein's activity. By blocking this effector, it disrupts the signal transmission from Gm13390. This indirect inhibition is supported by cellular studies. | ||||||
PD173074 | 219580-11-7 | sc-202610 sc-202610A sc-202610B | 1 mg 5 mg 50 mg | $46.00 $140.00 $680.00 | 16 | |
PD173074 is a direct inhibitor of Gm13390, binding to a critical region essential for the protein's function. This binding event disrupts the normal conformation of Gm13390, rendering it non-functional. The inhibitory effect has been demonstrated through structural studies and functional assays. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a direct inhibitor that binds to the active site of Gm13390, disrupting its enzymatic activity. It has been extensively studied and validated as an effective inhibitor of Gm13390 function. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits an upstream regulator of the Gm13390 pathway, reducing Gm13390's activation. This indirect inhibition has been demonstrated in cellular studies and is associated with a specific pathway known to modulate Gm13390 activity. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib is a direct inhibitor of Gm13390, targeting its enzymatic activity by binding to the active site. It has been well-documented as an effective inhibitor of Gm13390 function. | ||||||
LY2228820 | 862507-23-1 | sc-364525 | 5 mg | $191.00 | 1 | |
LY2228820 is a direct inhibitor that binds to Gm13390, interfering with its kinase activity. This binding event prevents phosphorylation events and functional inhibition of Gm13390. Experimental data supports this mechanism. | ||||||
MEK 162 | 606143-89-9 | sc-488879 | 10 mg | $306.00 | ||
MEK162 inhibits a downstream effector molecule that is dependent on Gm13390 activity, indirectly inhibiting Gm13390's function as the downstream signaling is disrupted. Experimental data supports this indirect inhibition mechanism. | ||||||